Status:

UNKNOWN

Characterization of Bleeding Disorders in EDS

Lead Sponsor:

University Health Network, Toronto

Conditions:

Ehlers-Danlos Syndrome

EDS

Eligibility:

All Genders

18+ years

Brief Summary

Ehlers-Danlos Syndrome (EDS) is a disease that weakens the connective tissues (i.e. tendons and ligaments) in the human body. EDS can make the joints loose and alter skin and wound healing. It can als...

Eligibility Criteria

Inclusion

  • Any adult (≥ 18 years) patient with a known diagnosis of Ehlers Danlos Syndrome (Subtypes Classical, Hypermobile, or Vascular) as per the 2017 International Classification of Ehlers Danlos Syndrome.

Exclusion

  • Subtypes of Ehlers Danlos Syndrome which are not Classical, Hypermobile, or Vascular.
  • Unable or unwilling to consent for the study

Key Trial Info

Start Date :

November 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2024

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT05434728

Start Date

November 1 2022

End Date

February 1 2024

Last Update

May 9 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

GoodHope EDS - Toronto General Hospital

Toronto, Ontario, Canada, M5G 2C4

Characterization of Bleeding Disorders in EDS | DecenTrialz